G1 TherapeuticsGTHX
Market Cap: $376M
About: G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
Employees: 100
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
94% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 17
44% more call options, than puts
Call options by funds: $8.9M | Put options by funds: $6.18M
10.39% more ownership
Funds ownership: 27.74% [Q1] → 38.14% (+10.39%) [Q2]
2% more funds holding
Funds holding: 86 [Q1] → 88 (+2) [Q2]
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
27% less capital invested
Capital invested by funds: $62.3M [Q1] → $45.5M (-$16.9M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Edward White 30% 1-year accuracy 36 / 120 met price target | 58%downside $3 | Buy Maintained | 25 Jun 2024 |
Needham Gil Blum 42% 1-year accuracy 65 / 156 met price target | 16%downside $6 | Buy Maintained | 25 Jun 2024 |
Needham Gil Blum 42% 1-year accuracy 65 / 156 met price target | 68%upside $12 | Buy Reiterated | 13 Jun 2024 |
Financial journalist opinion
Based on 3 articles about GTHX published over the past 30 days